Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody ... The marketing application for Enhertu (trastuzumab deruxtecan) is based on the results of the DESTINY-Breast06 trial ...

Mediolanum International Funds Ltd decreased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 67.7% ...

Great Diamond Partners LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.2% during the ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...